Nyxoah Appoints New CEO to Focus on U.S. Market

Nyxoah, a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026. The appointment reflects Nyxoah's continued evolution into a U.S.-focused commercial organization following FDA approval and the launch of Genio in the United States.

The appointment comes as Kelly brings more than 25 years of leadership experience to Nyxoah. He served as Chairman, President, and Chief Executive Officer of Teleflex Incorporated (NYSE: TFX) until January 2026, leading the company as President and Chief Executive Officer from January 2018 and as Chairman of the Board from May 2020. Kelly joined Teleflex in 2009 and held a series of senior operating roles, including President of EMEA, President, International, President, Americas, and Chief Operating Officer. Before Teleflex, he spent ten years at Hill-Rom Holdings, Inc. in senior management roles.

Kelly is a director of Enovis Corporation (NYSE: ENOV) and holds a Bachelor of Business Studies from the University of Limerick.

Kelly's appointment follows Nyxoah's successful completion of the BLAST OSA study, which led to the European CE Mark for the Genio system in 2019. The company completed two successful Initial Public Offerings (IPOs): one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, who were previously contraindicated in competitors' therapy. Additionally, the company announced positive outcomes from the DREAM IDE pivotal study in 2024 and received approval from the FDA in August 2025, with the treatment of CCC patients included in the warning section of their indications for use.

Nyxoah's lead solution, the Genio system, is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for OSA, a condition that is associated with increased mortality risk and cardiovascular comorbidities. The U.S. launch of Genio is still in its early stages, but the momentum seen in physician adoption gives Kelly great confidence in the future of the business.

Nyxoah's leadership and organizational structure are evolving to focus more on the U.S. market, a strategic shift that aligns with Kelly's extensive experience in scaling global businesses. The appointment of Kelly as Chief Executive Officer underscores Nyxoah's commitment to driving commercial performance and creating shareholder value in the United States.

Nyxoah, a medical technology company focused on the development and commercialization of innovative solutions to treat OSA, is entering a new chapter with Liam Kelly as its new Chief Executive Officer. Kelly's extensive experience in scaling organizations and driving commercial performance in the U.S. MedTech sector positions him well to lead Nyxoah as it continues to grow its presence in the United States. The appointment follows Nyxoah's successful completion of the BLAST OSA study, the completion of two successful IPOs, and the receipt of CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients. The U.S. launch of the Genio system, a leadless and battery-free hypoglossal neurostimulation therapy for OSA, is still in its early stages but is seeing significant momentum in physician adoption. Nyxoah's commitment to creating shareholder value and driving growth in the U.S. market is further strengthened by Kelly's appointment as Chief Executive Officer.